Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gensight Biologics SA
Free Cash Flow
Gensight Biologics SA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Free Cash Flow
-€9.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Free Cash Flow
-€57.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Free Cash Flow
-€29.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-7%
|
|
|
Inventiva SA
PAR:IVA
|
Free Cash Flow
-€162m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Free Cash Flow
-$121m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-14%
|
|
|
Abivax SA
PAR:ABVX
|
Free Cash Flow
-€154.7m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-26%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Free Cash Flow?
Free Cash Flow
-9.2m
EUR
Based on the financial report for Dec 31, 2025, Gensight Biologics SA's Free Cash Flow amounts to -9.2m EUR.
What is Gensight Biologics SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
9%
Over the last year, the Free Cash Flow growth was 29%. The average annual Free Cash Flow growth rates for Gensight Biologics SA have been 35% over the past three years , 9% over the past five years .
